… of other checkpoints able to inhibit effective anti-tumor immune … Monalizumab is an anti-NKG2A
blocking mAb that not only … Tiragolumab is a novel immune checkpoint inhibitor designed …

… Anti-tumor Immunity by Unleashing Both T and NK Cells. … , exhibit a broad anti-tumor activity
against several tumor types … that this inhibitory axis can be lifted with anti-NKG2A treatment (…

… capacity to enhance anti-tumor immunity by unleashing both NK … anti-tumor cytotoxicity
[164]. This analysis suggests that the increased affinity of highly selective anti-NKG2A KSQ mAbs …

… be sufficient to unleash a potent anti-tumour immune response by … Immune checkpoint
inhibitors (ICIs) have drastically … an anti-NKG2A domain derived from anti-NKG2A mAbs attached …

… anti-tumor immune responses in many cancer models, including T-cell transfer therapies,
vaccines, and immune checkpoint inhibitors … be to combine anti-NKG2A and anti-TIGIT mAbs to …

… , anti-NKG2A antibodies have shown limited clinical response. In the pursuit of enhancing
NK cell-mediated anti-tumor … cancer treatment, and immune checkpoint inhibitors and CAR-T …

… inhibitory receptors, which are expressed in a programmed way (11). As revealed, CTLA-4
and PD-1 inhibitory … each inhibitory receptor, resulting in distinct profiles of immune pathology …

… and anti-NKG2A mAbs) can induce potent anti-tumor immunity … -JAK pathway might unleash
NK cell anti-tumor efficacy, and … checkpoint inhibitor therapies promote the direct anti-tumor …

… essential role in shaping a complete anti-tumor immune response and the presence of tumor-…
One of the central intervention strategies involves the anti-NKG2A antibody monalizumab. …

… blocking NKG2A can effectively unleash functions of these … Therefore, anti-NKG2A mAb
monalizumab could represent a … the initiation or regulation of anti-tumor immunity, but primarily …